Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 229 of 6351
-
Shielding immune cells during radiation: a new strategy against esophageal cancer?
Disease control Recruiting nowEsophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignant tumors. Although neoadjuvant chemoradiotherapy combined with surgery has significantly improved the survival rate of patients with locally advanced esophageal cancer, approximately half of the patie…
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for head and neck cancer: experimental drug petosemtamab enters final testing
Disease control OngoingThis is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Phase 3 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
CRISPR therapy takes aim at stubborn high cholesterol in first human trial
Disease control Recruiting nowThis is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.
Phase 1 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Sep 10, 2026 04:00 UTC
-
Can two cancer drugs team up to slow a rare sarcoma?
Disease control Recruiting nowDedifferentiated liposarcomas (DDLPS) are aggressive soft tissue sarcomas with no effective medical treatment options. Immunotherapy with checkpoint inhibitors, so-called PD-1 inhibitors, have shown some effect in DDLPS in previous studies. Effect of immunotherapy can be improve…
Phase 2 • Sponsor: Lund University Hospital • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a new drug calm the storm of bipolar mania?
Symptom relief CompletedThis is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteri…
Phase 3 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
Gene-Editing shot aims to fix lung and liver damage in rare disease
Disease control Recruiting nowThis is a Phase 1/2, multicenter, open-label, dose-exploration (Phase 1) and dose-expansion (Phase 2) study to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or liver disease and to determine the optimal …
Phase 1/2 • Sponsor: Beam Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New antibody combo aims to stall multiple Myeloma's return
Disease control Recruiting nowThe purpose of this study is to evaluate the effects of the addition of SG301 injection to pomalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma.
Phase 3 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Can a Two-Drug attack shrink tough lung cancers?
Disease control Recruiting nowThis study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 monoclonal antibody combination therapy in patients with extensive-stage small cell lung cancer.
Phase 2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Digital nudges aim to optimize heart failure care
Disease control By invitation onlyThis study investigates the impact of a nudge-based intervention on improving guideline directed medical therapy (GDMT) prescription among cardiologists. Using a stepped wedge randomized controlled trial design, we assess whether digital decision support-leveraging home monitorin…
Sponsor: Medisch Spectrum Twente • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Radioactive injection targets Hard-to-Treat tumors in new trial
Disease control Recruiting nowThis is a multicenter, single-arm, two-part study designed to evaluate the safety and efficacy of Lutetium \[177Lu\] Oxyoctreotide Injection in patients with inoperable, locally advanced or metastatic, progressive, advanced somatostatin receptor (SSTR) positive neuroendocrine neo…
Phase 2/3 • Sponsor: Sinotau Pharmaceutical Group • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Gene therapy trial hopes to ease Parkinson's symptoms
Disease control Recruiting nowThe objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.
Phase 2 • Sponsor: AskBio Inc • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can a Two-Drug attack shrink Hard-to-Treat head and neck tumors?
Disease control Recruiting nowThis study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 monoclonal antibody combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (non-nasopharyngeal carcinoma) and other solid tumors.
Phase 2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New targeted therapy aims at Hard-to-Treat bile duct cancers
Disease control OngoingThis study was to evaluate the efficacy and safety of SHR-A1811 in patients with locally advanced unresectable or recurrent metastatic BTC with HER2 expression / amplification who failed first-line or second-line systemic treatment.
Phase 2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
A 4-Week lifestyle fix to stop diabetes in its tracks?
Prevention Recruiting nowSmall Steps for Big Changes (SSBC) is a diet and exercise counselling program that significantly reduces the risk of developing Type 2 Diabetes (T2D). In partnership with YMCAs in Canada spanning 8 provinces, the aim of this study is to scale-up program delivery and evaluate the …
Sponsor: University of British Columbia • Aim: Prevention
Last updated Aug 05, 2026 00:00 UTC
-
Organoid-Guided drug trial offers hope for cystic fibrosis patients with rare mutations
Disease control CompletedCF is caused by mutations in the gene that encodes the 'Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)' channel. To re-establish the function of this complex chloride channel, typically two to three drug modes of action are needed. To date, clinical studies of CFTR mo…
Phase 2 • Sponsor: Kors van der Ent • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Could a gut microbiome transplant ease axial spondyloarthritis?
Disease control Recruiting nowAlthough biologic therapy have revolutionized the treatment of Spondyloarthrtitis (SpA), many patients do not experience complete relief of SpA related complaints. It has been established that patients with SpA have an altered composition of microorganisms (microbiota) in the gu…
Phase 2 • Sponsor: University Hospital of North Norway • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Hope for muscle strength: new drug targets myotonic dystrophy
Disease control CompletedA Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
Phase 3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a new injection tame prostate cancer by cutting testosterone?
Disease control CompletedA phase 3, multi-center, single-group, open-label study to evaluate the efficacy and safety of DKF-MA102 in patients with prostate cancer.
Phase 3 • Sponsor: Dongkook Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug duo aims to control lymphoma without chemo
Disease control Recruiting nowTo learn if the chemotherapy-free combination of pirtobrutinib (also called LOXO-305) and rituximab can help provide long term remission in low and intermediate risk MCL.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can a glue stop spinal fluid leaks after surgery?
Disease control CompletedThis is a prospective, multicenter, single-blind, randomized controlled superiority clinical trial of dural medical adhesive for watertight sealing after primary spinal dural repair to prevent cerebrospinal fluid (CSF) leakage. A total of 141 patients with intraoperative CSF leak…
Phase 3 • Sponsor: Medprin Regenerative Medical Technologies Co., Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC